Vaxart (OTCMKTS:VXRT – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Vaxart to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Profitability
This table compares Vaxart and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxart | 16.02% | 35.14% | 17.10% |
| Vaxart Competitors | -2,398.26% | -203.62% | -15.08% |
Insider & Institutional Ownership
18.0% of Vaxart shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.8% of Vaxart shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Vaxart and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxart | 0 | 1 | 0 | 0 | 2.00 |
| Vaxart Competitors | 7845 | 13798 | 25819 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.35%. Given Vaxart’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Vaxart has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares Vaxart and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Vaxart | $237.26 million | $16.33 million | 2.77 |
| Vaxart Competitors | $18.73 billion | $3.24 billion | 559.14 |
Vaxart’s rivals have higher revenue and earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Vaxart has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Vaxart’s rivals have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.
Summary
Vaxart rivals beat Vaxart on 9 of the 13 factors compared.
Vaxart Company Profile
Vaxart, Inc. is a clinical-stage biotechnology company developing oral vaccines for infectious diseases. Its proprietary platform is designed to deliver vaccine candidates in tablet form and to stimulate immune responses at mucosal surfaces as well as throughout the body. The company’s investigational programs have included vaccines for norovirus, seasonal influenza and COVID-19. These candidates remain in development and are not approved vaccines. Based in South San Francisco, California, Vaxart focuses on research and development and may work with external partners to advance its vaccine programs.
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
